$CBMC news from yesterday - this can break a penny soon, good things going on at CBMC!
Calypte Biomedical and Maxim Biomedical Announce Joint Distribution of Incidence Testing Assays
GlobeNewswire
12:00 PM ET
Calypte Biomedical Corporation (OTCBB:CBMC) and Maxim Biomedical Inc. today announced a reciprocal distribution agreement under which customers may purchase from either company, on the same terms, both Calypte's Aware(TM) BED EIA HIV-1 Incidence Test and Maxim's HIV-1 Limiting Antigen (LAg)-Avidity EIA Kit.
The two assays are produced by their respective manufacturers under license from the Centers for Disease Control (Atlanta, GA), and use different biomarkers to classify HIV-positive blood, serum or plasma specimens as either recent or long-term infections. This information can be used to derive a measure of the number of new HIV infections in a given population (that is, "HIV incidence").
"Traditional measures of incidence, such as cohort studies, are expensive and time consuming. Cross-sectional assays such as the BED and LAg offer public health authorities faster, more cost effective access to information that is critical for monitoring the epidemic, allocating resources and evaluating intervention programmes," said Adel Karas, Chairman and CEO of Calypte.
The LAg assay is a newer methodology which is still being validated, whereas the BED assay has the advantage of more than half a decade's worth of predicate data. The partners anticipate that many laboratories which are familiar with BED will want to make their own side-by-side comparisons. In addition, r ecent research has indicated that algorithms which use both BED and LAg in series can provide significant improvements in specificity.
Calypte Biomedical and Maxim Biomedical Announce Joint Distribution of Incidence Testing Assays
GlobeNewswire
12:00 PM ET
Calypte Biomedical Corporation (OTCBB:CBMC) and Maxim Biomedical Inc. today announced a reciprocal distribution agreement under which customers may purchase from either company, on the same terms, both Calypte's Aware(TM) BED EIA HIV-1 Incidence Test and Maxim's HIV-1 Limiting Antigen (LAg)-Avidity EIA Kit.
The two assays are produced by their respective manufacturers under license from the Centers for Disease Control (Atlanta, GA), and use different biomarkers to classify HIV-positive blood, serum or plasma specimens as either recent or long-term infections. This information can be used to derive a measure of the number of new HIV infections in a given population (that is, "HIV incidence").
"Traditional measures of incidence, such as cohort studies, are expensive and time consuming. Cross-sectional assays such as the BED and LAg offer public health authorities faster, more cost effective access to information that is critical for monitoring the epidemic, allocating resources and evaluating intervention programmes," said Adel Karas, Chairman and CEO of Calypte.
The LAg assay is a newer methodology which is still being validated, whereas the BED assay has the advantage of more than half a decade's worth of predicate data. The partners anticipate that many laboratories which are familiar with BED will want to make their own side-by-side comparisons. In addition, r ecent research has indicated that algorithms which use both BED and LAg in series can provide significant improvements in specificity.
